Pharmacokinetics-Pharmacodynamics of the Helicase-Primase Inhibitor Pritelivir following Treatment of Wild-Type or Pritelivir-Resistant Virus Infection in a Murine Herpes Simplex Virus 1 Infection Model

Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection

(2014) Anna Wald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase–primase inhibitor pritelivir

(2013) Hugh J. Field et al.   ANTIVIRAL RESEARCH

Helicase–primase inhibitors as the potential next generation of highly active drugs against herpes simplex viruses

(2011) Alexander Birkmann et al.   Future Virology

Effects of therapy using a helicase–primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant

(2010) Soumi Sukla et al.   ANTIVIRAL RESEARCH

Herpes Simplex Virus-1 Helicase−Primase: Roles of Each Subunit in DNA Binding and Phosphodiester Bond Formation

(2009) Nisha A. Cavanaugh et al.   BIOCHEMISTRY

A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure

(2009) S. Biswas et al.   JOURNAL OF GENERAL VIROLOGY

Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses

(2008) Emilie Frobert et al.   ANTIVIRAL RESEARCH

Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase–primase inhibitors, variously affect virus growth rate and pathogenicity

(2008) Subhajit Biswas et al.   ANTIVIRAL RESEARCH

PK/PD: new insights for antibacterial and antiviral applications

(2008) S SCHMIDT et al.   CURRENT OPINION IN PHARMACOLOGY

A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral target

(2008) Subhajit Biswas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY